The combination of the oral antiviral nirmatrelvir and the protease inhibitor ritonavir (Paxlovid – Pfizer) has been available in the US since late December, 2021. In the clinical trial that led to the Emergency Use Authorization for Paxlovid, the drug decreased hospitalization or death, compared to placebo, by 88%.1 US COVID-19 deaths in 2022 averaged […]
The official blog of The Medical Letter
More@MedLetter 